TCM
COGT icon

Tekla Capital Management’s Cogent Biosciences COGT Stock Holding History

Tekla Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-146,911
Closed -$1.32M – 173
2022
Q2 		$1.32M Buy
+146,911
New +$1M 0.05% 126
2021
Q3 		– Sell
-537,742
Closed -$4.36M – 180
2021
Q2 		$4.36M Hold
537,742
– – 0.14% 125
2021
Q1 		$4.72M Hold
537,742
– – 0.16% 120
2020
Q4 		$6.04M Buy
537,742
+261,948
+95% +$2.88M 0.21% 110
2020
Q3 		$2.58M Buy
+275,794
New +$2.88M 0.1% 140

Other funds holding COGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Tekla Capital Management's COGT Position: Q3 2022 in Review

Tekla Capital Management sold out of Cogent Biosciences (COGT) in Q3 2022, closing a stake of 146,911 shares — an estimated $1.32M sold.

Tekla Capital Management first reported a position in COGT in Q3 2020 and held it in 5 quarters. The position peaked at $6.04M in Q4 2020. 134 funds tracked by Wall St. Rank hold COGT as of Q3 2022.

  • Tekla Capital Management reported no remaining Cogent Biosciences position as of Q3 2022 after selling out during the quarter.
  • Tekla Capital Management sold 146,911 Cogent Biosciences shares in Q3 2022, an estimated $1.32M.
  • Tekla Capital Management first reported a position in Cogent Biosciences in Q3 2020 and held it in 5 quarters.
  • Tekla Capital Management's Cogent Biosciences position peaked at $6.04M in Q4 2020.
  • 134 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2022.

Based on Tekla Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.